In 2017, the total incident cases of Multiple Myeloma in 8MM was 85,971. The incident cases of Multiple Myeloma in the United States was found to be 30,271 in 2017.
The market size of Multiple Myeloma in 8MM was USD 14,111 million in 2017.
The key players in the Multiple Myeloma Market includes GlaxoSmithKline, Bristol-Myers Squibb, Bluebird bio, AbbVie, Roche, Janssen Biotech, Nanjing Legend Biotech, Oncopeptides AB, Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Celgene, RAPA Therapeutics, Pfizer, Cellectar Biosciences, BioLineRx, Aduro Biotech, ExCellThera, Takeda, Glenmark, Poseida Therapeutics, Amgen, Precision BioSciences, Juno Therapeutics, Molecular Partners AG, Cartesian Therapeutics, AstraZeneca, MorphoSys AG, I-Mab Biopharma and Chipscreen Biosciences.
For more detailed information on Multiple Myeloma Market, visit: https://www.delveinsight.com/report-store/multiple-myeloma-market